All In Biotech

Drug Trial Radar · NCT07196163

An Exploratory Study of Golidocitinib in Adult Patients With ITP

An Exploratory Clinical Study of Golidocitinib in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Oct 30, 2028

Study completion Oct 30, 2029

Sponsor

Lead sponsor
Peking University People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter clinical study to evaluate the safety and efficacy of golidocitinib in patients with primary immune thrombocytopenia (ITP). The study consists of two parts: Part A dose escalation and Part B dose expansion. Part A is designed to obtain the safety profile of golidocitinib in patients with ITP and the recommended dose for the randomized cohort in Part B. Part B is a randomized, double-blind, placebo-controlled study, and the primary objective of this part is to evaluate the preliminary efficacy of golidocitinib in patients with ITP.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • GolidocitinibDrug

    Golidocitinib will be administered orally as capsules in a 28-day cycle.

  • PlaceboDrug

    Placebo will be administered orally as capsules in a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence and severity of Adverse Events (AEs)Time frame: 1 year
  2. Part B: Durable response rateTime frame: up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Insititute of Hematology, Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.